Natalie Savona
Medical · New Canaan, CTNPI 1841657632
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 714 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 57 manufacturers reported payments, led by AbbVie at 34.4% of the total. Among medical clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 714 payments — averaging $22.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- AstraZeneca$810
- Exact Sciences$787
- Pfizer$705
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$635
- Merck$626
- plus $7K from 51 others
What the payments were for
- Food & beverage$15,64599%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$244
- VRAYLAR$118
- QULIPTA$115
- UBRELVY$115
- COREVALVE EVOLUT R$110
- FREESTYLE LIBRE 3$108
How this compares
$15,745 in reported general payments places this provider in the 95th percentile of 592 medical providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,580 |
| Alprazolam | 141 | $917 |
| Zolpidem Tartrate | 93 | $911 |
| Ezetimibe | 22 | $870 |
| Atorvastatin Calcium | 55 | $857 |
| Rosuvastatin Calcium | 48 | $744 |
| Testosterone Cypionate | 14 | $737 |
| Levothyroxine Sodium | 55 | $727 |
| Pantoprazole Sodium | 38 | $685 |
| Methylprednisolone | 75 | $659 |
| Eszopiclone | 34 | $637 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $563 |
| Olmesartan Medoxomil | 12 | $543 |
| Azithromycin | 98 | $475 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 16 | $424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $114 | $4,58012 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $66 | $72755 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 592 medical providers in Connecticut.
Other medical in New Canaan
- Shilpa DesaiStamford$215K
- Gregory RauNew Haven$211K
- John JasinskiNorwalk$185K
- Brianna PaesanoStamford$153K
- Debra SullivanDerby$100K
- Ryan DonovanNew Haven$75K
- Jonica PagnuccoWaterbury$32K
- Alyssa GreenleafSouthington$26K
- Mark VolpeSuffield$21K
- Josephine DiazSuffield$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.